Sign In
Buy QGEN
$36.45
+0.760 (+2.13%)
At Close: Jun 03, 2026
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis
04:05pm, Wednesday, 27'th Nov 2024
QIAGEN introduces market's first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custo
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
10:56am, Monday, 25'th Nov 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns
10:21am, Friday, 22'nd Nov 2024
To support internal growth, QGEN heavily invests in R&D for the menu expansion of its key platforms.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
06:50am, Friday, 22'nd Nov 2024
Investors feel optimistic about QGEN's growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is concerning.
QGEN Collaborates With McGill University Centre: Stock to Gain?
12:21pm, Wednesday, 13'th Nov 2024
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock
10:20am, Monday, 11'th Nov 2024
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
10:46am, Friday, 08'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript
03:58pm, Thursday, 07'th Nov 2024
Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sacke
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up
11:25am, Thursday, 07'th Nov 2024
QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics
09:30pm, Wednesday, 06'th Nov 2024
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compar
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates
07:40pm, Wednesday, 06'th Nov 2024
Qiagen (QGEN) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.52 per share a year ago.
Diagnostics firm Qiagen reports rise in third-quarter revenue
04:35pm, Wednesday, 06'th Nov 2024
Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel
10:35am, Monday, 04'th Nov 2024
QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:21am, Monday, 04'th Nov 2024
Beyond analysts' top -and-bottom-line estimates for Qiagen (QGEN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
01:30am, Monday, 04'th Nov 2024
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successf
